Find A Clinical Trial
Disease Type: Solid Tumors All
A PHASE 1B/2, OPEN-LABEL, SAFETY, TOLERABILITY AND EFFICACY STUDY OF NC410 PLUS PEMBROLIZUMAB FOR PARTICIPANTS WITH ADVANCED UNRESECTABLE AND/OR METASTATIC IMMUNE CHECKPOINT INHIBITOR (ICI) REFRACTORY SOLID TUMORS OR ICI NAIVE MSS/MSI-LOW SOLID TUMORS (NC410-02)
Principal Investigator
Alexander I. Spira, MD, PhD, FACPAn Open-Label, Multicenter, First-in-Human, Dose-Escalation, Phase 1 Study of INBRX-106 and INBRX-106 in Combination with Pembrolizumab in Subjects with Locally Advanced or Metastatic Solid Tumors
Principal Investigator
Alexander I. Spira, MD, PhD, FACP“A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion Study of Intravenously Administered 23ME-00610 in Patients with Advanced Solid Malignancies”
Principal Investigator
Alexander I. Spira, MD, PhD, FACPA Phase 2 multi-center open-label basket trial of ABI-009 (nab-sirolimus) for adult and adolescent patients with solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes
Principal Investigator
Alexander I. Spira, MD, PhD, FACPA Multicenter, Open-Label, Extension Study of the Safety and Tolerability of Sitravatinib Alone or in Combination with Other Anticancer Therapies in Patients with Advanced or Metastatic Solid Malignancies
Principal Investigator
Alexander I. Spira, MD, PhD, FACPA First-in-Human, Open-Label, Dose Escalation and Expansion Study of Orally Administered JBI-802 in Patients with Advanced Solid Tumors
Principal Investigator
Alexander I. Spira, MD, PhD, FACPA Phase I Study of ASP3082 in Participants with Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies with KRAS G12D
Principal Investigator
Alexander I. Spira, MD, PhD, FACPA Phase 1 Study of SGN-ALPV in Advanced Solid Tumors
Principal Investigator
Alexander I. Spira, MD, PhD, FACPPhase 1/1b, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects with Advanced KRAS G12C Mutant Solid Tumors